The First Case of Pulmonary Mucormycosis Caused by Lichtheimia ornata

참고문헌 (10)

1. Skiada A, "Zygomycosis in Europe : analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology(ECMM)Working Group on Zygomycosis between 2005 and 2007", Clin Microbiol Infect, 17, pp.1859~1867 (2011)
2. Alvarez E, "Spectrum of zygomycete species identified in clinically significant specimens in the United States", J Clin Microbiol, 47, pp.1650~1656 (2009)
3. Schwartze VU, "Lichtheimia species exhibit differences in virulence potential", PLoS One, 7, pp.e40908~ (2012)
4. Pan J, "First case of rhinocerebral mucormycosis caused by Lichtheimia ornata, with a review of Lichtheimia infections", Mycopathologia, 185, pp.555~567 (2020)
5. Chowdhary A, "Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors", Mycoses, 66, pp.515~526 (2023)
6. Tissot F, "ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients", Haematologica, 102, pp.433~444 (2017)
7. CLSI, "Reference method for broth dilution antifungal susceptibility testing of filamentous fungi" (2017), Clinical and Laboratory Standards Institute
8. CLSI, "Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing" (2018), Clinical and Laboratory Standards Institute
9. Alastruey-Izquierdo A, "Antifungal susceptibility profile of human-pathogenic species of Lichtheimia", Antimicrob Agents Chemother, 54, pp.3058~3060 (2010)
10. Subcommittee on antifungal susceptibility testing of the ESCMID, "EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidiaforming moulds", Clin Microbiol Infect, 14, pp.982~984 (2008)

관련 논문AI추천